Mooradian A D
St Louis V.A. Medical Center, Missouri, USA.
Drugs. 1996 Jun;51(6):931-41. doi: 10.2165/00003495-199651060-00002.
Non-insulin-dependent diabetes (NIDDM) is a common problem in the elderly. The discovery of several classes of oral antidiabetic agents has increased the prospects of achieving better control of hyperglycaemia with reduced risk of severe adverse events. Some of these agents, such as acarbose or miglitol, do not cause hypoglycaemia and act locally in the gut. As such they are safer agents. On the other hand, the low cost of some sulphonylurea agents and a once or twice daily administration schedule make them an attractive option. Metformin appears to be especially useful in obese insulin-resistant patients with NIDDM. However, obesity is not as much of a problem in the elderly as it is in middle-aged patients, and contraindications to the use of metformin are common in the elderly. The use of a combination of 2 or 3 oral antidiabetic agents to delay the need for insulin therapy is now possible. The long term effects of this approach are not known and the cost of polypharmacy is of concern.
非胰岛素依赖型糖尿病(NIDDM)在老年人中是一个常见问题。几类口服抗糖尿病药物的发现增加了更好地控制高血糖且降低严重不良事件风险的前景。其中一些药物,如阿卡波糖或米格列醇,不会引起低血糖,且在肠道局部起作用。因此,它们是更安全的药物。另一方面,一些磺脲类药物成本低且每日只需服用一到两次,这使其成为一个有吸引力的选择。二甲双胍似乎对患有NIDDM的肥胖胰岛素抵抗患者特别有用。然而,肥胖在老年人中不像在中年患者中那样是个大问题,而且老年人中使用二甲双胍的禁忌很常见。现在可以联合使用2种或3种口服抗糖尿病药物来推迟胰岛素治疗的需求。这种方法的长期效果尚不清楚,且联合用药的成本令人担忧。